[1] LIPINSKI C A. Drug-like properties and the causes of poor solubility and poor permeability [J]. J Pharmacol Toxicol Methods, 2000, 44(1):235-249. [2] PARDRIDGE W M. Drug targeting to the brain [J]. Pharmacol Res, 2007, 24(9): 1733-1744. [3] LI J Y, BOADO R J, PARDRIDGE W M. Cloned blood-brain barrier adenosine transporter is identical to the rat concentrative Na+ nucleoside cotransporter CNT2 [J]. J Cereb Blood Flow Metab, 2001, 21(8):929-936. [4] TAMAI I, TSUJI A. Transporter-mediated permeation of drugs across the blood-brain barrier [J]. J Pharm Sci, 2000, 89(11):1371-1388. [5] LOCKMAN P R, KOZIARA J M, MUMPER R J, et al. Nanoparticle surface charges alter blood-brain barrier integrity and permeability [J]. Drug Target, 2004, 12(9-10):635-641. [6] PARDRIDGE W M. Drug and gene targeting to the brain with molecular trojan horses [J]. Nat Rev Drug Discov, 2002, 1(2):131-139. [7] CONNER S D, SCHMID S L. Regulated portals of entry into the cell [J]. Nature, 2003, 422 (6927): 37-44. [8] CUERVO A M. Autophagy: many paths to the same end [J]. Mol Cell Biochem, 2004, 63(1-2): 55-72. [9] DE BOER A G, GAILLARD P J. Drug targeting to the brain [J]. Annu Rev Pharmacol Toxicol, 2007, 47(1):323-355. [10] MOOS T, MORGAN E H. Transferrin and transferrin receptor function in brain barrier systems [J]. Cell Mol Neurobiol, 2000, 20(1):77-95. [11] SHIN S U, FRIDEN P, MORAN M, et al. Transferrin-antibody fusion proteins are effective in brain targeting [J]. Proc Nat Acad Sci, 1995, 92(7):2820-2924. [12] MISHRA V, MAHOR S, RAWAT A, et al. Targeted brain delivery of AZT via transferrin anchored pegylated albumin nanoparticles [J]. J Drug Target, 2006, 14(1):45-53. [13] QIAN Z M, LI H Y, SUN H Z, et al. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway [J]. Pharmacol Rev, 2002, 54(4):561-587. [14] ZHANG Y, PARDRIDGE W M. Blood-brain barrier targeting of BDNF improves motor function in rats with middle cerebral artery occlusion [J]. Brain Res, 2006, 1111(1):227-229. [15] SHI N, BOADO R J, PARDRIDGE W M. Receptor-mediated gene targeting to tissues <>in vivo following intravenous administration of pegylated immunoliposomes [J]. Pharm Res, 2001, 18(8):1091-1095. [16] ZHANG Y, PARDRIDGE W M. Delivery of beta-galactosidase to mouse brain via the blood-brain barrier transferrin receptor [J]. J Pharmacol Exp Ther, 2005, 313(3):1075-1081. [17] LEE H J, ZHANG Y, ZHU C N, et al. Imaging brain amyloid of Alzheimer disease <>in vivo in transgenic mice with an A beta peptide radiopharmaceutical [J]. J Cereb Blood Flow Metab, 2002, 22(2):223-231. [18] LEE H J, ENGELHARDT B, LESLEY J, et al. Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse [J]. J Pharmacol Exp Ther, 2000, 292(3):1048-1052. [19] COLOMA M J, LEE H J, KURIBARA A, <>et al. Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor [J]. Pharm Res, 2000, 17(3):266-274. [20] BOADO R J, ZHANG Y F, ZHANG Y, et al. Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier [J]. Biotechnol Bioeng, 2007, 96(2):381-391. [21] GAILLARD P J, VISSER C C, DE BOERDE A G. Targeted delivery across the blood–brain Barrier [J]. Expert Opin Drug Deliv, 2005, 2(2):299-309. [22] RICHARDSON D R, MORGAN E H. The transferrin homologue, melanotransferrin p97, is rapidly catabolized by the liver of the rat and does not effectivelydonate iron to the brain [J]. Biochim Biophys Acta, 2004, 1690(2):124-133. [23] GABATHULER R, ARTHUR G, KENNARD M, et al. Development of a potential vector NeuroTrans to deliver drugs across the blood-brain barrier [J]. Int Cong Series, 2005, 1277(1):171-184. [24] PAN W, KASTIN A J, ZANKEL T C, et al. Efficient transfer of receptorassociated protein (RAP) across the blood-brain barrier [J]. J Cell Sci, 2004, 117(21):5071-5078. [25] GAILLARD P J, BRINK A, DE BOER A G. Diphtheria toxin receptor-targeted brain drug delivery [J]. Int Cong Series, 2005, 1277(1):185-198. [26] BUZZI S, RUBBOLI D, BUZZI G, et al. CRM197 Nontoxic diphtheria toxin: effects on advanced cancer patients [J]. Cancer Immunol Immunother, 2004, 53(11): 1041-1048. [27] LUCIANI A, OLIVIER J C, CLEMENT O, et al. Glucosereceptor MR imaging of tumors: study in mice with PEGylated paramagnetic niosomes [J]. Radiology, 2004, 231(1): 135-142. [28] JONES A R, SHUSTA E V. Blood-brain barrier transport of therapeutics via receptor-mediation [J]. Pharmacol Res, 2007, 24(9): 1759-1771. （ 收稿日期 ： 2009-04-10 ）
PDF(2506 KB)
